CymaBay Therapeutics Inc CBAY
News
CymaBay's stock surges as Gilead reaches $4.3 billion deal for liver-drug developer
Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion
CymaBay Shares Rise 7% After Revised Breakthrough Therapy Designation
CymaBay Therapeutics stock jumps as rare liver disease treatment shows positive results